S&P 500

5.667,20

0,64%

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Allos Therapeutics, Inc. (MM) (ALTH)
Allos Therapeutics, Inc. (MM) (ALTH) Notícias

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:ALTH

<< Anterior 1 2 3 4 5 6 7 8 9 10 11 12 13 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
23/10/2006	08:29	PR Newswire (US)	Allos Therapeutics Announces ENRICH Trial Update	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/10/2006	10:00	PR Newswire (US)	Allos Therapeutics Receives FDA Fast Track Designation for PDX for the Treatment of T-cell Lymphoma	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
29/08/2006	09:30	PR Newswire (US)	Allos Therapeutics to Present at Upcoming Investor Conferences	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
29/08/2006	09:00	PR Newswire (US)	Allos Therapeutics Initiates Pivotal Phase 2 Study of PDX in Patients With Peripheral T-cell Lymphoma	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
28/08/2006	09:00	PR Newswire (US)	Allos Therapeutics Completes Patient Enrollment in Pivotal Phase 3 Study of EFAPROXYN(TM) in Women with Brain Metastases Origin	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
07/08/2006	09:00	PR Newswire (US)	Allos Therapeutics Reports Second Quarter 2006 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
02/08/2006	09:30	PR Newswire (US)	Allos Therapeutics Receives Special Protocol Assessment for Pivotal Phase 2 Study of the Company's Novel Antifolate PDX in Pati	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
26/07/2006	10:00	PR Newswire (US)	FDA Grants Orphan Drug Designation to Allos Therapeutics' Novel Antifolate PDX for the Treatment of T-cell Lymphoma	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
14/06/2006	09:00	PR Newswire (US)	Retrospective Analysis of Allos Therapeutics' Phase 3 REACH Study Finds Positive Correlation between Patient Outcomes and EFAPR	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
13/06/2006	09:12	PR Newswire (US)	Allos Therapeutics Files Shelf Registration Statement	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
07/06/2006	10:00	PR Newswire (US)	Allos Therapeutics to Present at the 2006 Needham & Company Biotechnology Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
05/06/2006	20:07	PR Newswire (US)	Allos Therapeutics Appoints James V. Caruso as Chief Commercial Officer	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
05/06/2006	10:00	PR Newswire (US)	Allos Therapeutics' EFAPROXYN(TM) Found to Reduce Tumor Hypoxia and HIF-1-alpha Expression in Human Breast Cancer Xenografts	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
25/05/2006	17:33	PR Newswire (US)	Allos Therapeutics Reports Restricted Stock Grant Under Nasdaq Marketplace Rule 4350	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
09/05/2006	09:00	PR Newswire (US)	Allos Therapeutics Reports First Quarter 2006 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/04/2006	09:00	PR Newswire (US)	Interim Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 3 Trial	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
10/03/2006	10:00	PR Newswire (US)	Allos Therapeutics Appoints Paul L. Berns as President and CEO	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
06/03/2006	10:00	PR Newswire (US)	Allos Therapeutics Reports 2005 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
01/03/2006	10:00	PR Newswire (US)	Allos Therapeutics to Present at the 2006 Cowen Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
14/02/2006	11:00	PR Newswire (US)	Scheduled Combination of Allos Therapeutics' Pralatrexate Plus Gemcitabine Proves Superior to Methotrexate Plus Cytarabine in Mo	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
01/02/2006	11:00	PR Newswire (US)	Allos Therapeutics to Present at the 2006 BIO CEO & Investor Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
16/01/2006	22:22	PR Newswire (US)	Allos Therapeutics Announces CEO Succession Plans	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/01/2006	11:00	PR Newswire (US)	Results Published in Journal of Clinical Oncology Affirm Survival Benefit of EFAPROXYN(TM) in Patients with Brain Metastases Ori	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
12/12/2005	11:02	PR Newswire (US)	Retrospective Analysis Finds EFAPROXYN(TM) Extends Survival With Quality of Life in Patients With Brain Metastases Originating F	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
12/12/2005	11:00	PR Newswire (US)	PDX Shows Promising Activity in Patients With Resistant T-Cell Lymphomas	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/11/2005	11:02	PR Newswire (US)	Allos Therapeutics Appoints Timothy P. Lynch to Board of Directors	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/11/2005	11:01	PR Newswire (US)	Interim Phase 1 Data on RH1 Presented at AACR-NCI-EORTC Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
16/11/2005	11:00	PR Newswire (US)	Data From Phase 1 Clinical Trial of PDX (Pralatrexate) to be Presented at American Society of Hematology Annual Meeting	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
09/11/2005	11:02	PR Newswire (US)	Allos Therapeutics Reports Third Quarter 2005 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
08/11/2005	11:02	PR Newswire (US)	Data on EFAPROXYN(TM) and RH1 to be Presented at Upcoming Scientific Conferences	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)